Please login to the form below

Not currently logged in
Email:
Password:

antitrust

This page shows the latest antitrust news and features for those working in and with pharma, biotech and healthcare.

It’s only money

It’s only money

problem breached European Union competition rules - this ruling upheld a 2014 decision by Italy’s antitrust authority that the drugmakers colluded to boost sales of Lucentis by discrediting the cheaper Avastin

Latest news

More from news
Approximately 4 fully matching, plus 84 partially matching documents found.

Latest Intelligence

  • Risky business for pharma Risky business for pharma

    to consider, including but not limited to bribery and corruption, money laundering, competition and antitrust, cybersecurity, data privacy and regulation and compliance. ... Villareal also cited “[c] ompetition and antitrust issues. as a global risk

  • Deal Watch October 2015 Deal Watch October 2015

    This deal will combine the second and third largest drug store operators in the US and as a result it will no doubt be scrutinised by the US antitrust authorities. ... Echoing some of the hefty termination provisions we saw last year in big pharma deals,

  • Pharma deals in July 2015 Pharma deals in July 2015

    However, Teva's deal with Allergan is not over yet. It is subject to review by antitrust regulators of the combined generics portfolio.

  • Pharma deals in June 2015 Pharma deals in June 2015

    When GSK acquired two additional rival meningitis vaccines from Novartis, namely Menveo and Bexsero, the European Commission and other antitrust regulators were concerned that this gave GSK too much power in

  • Pharma deals in May 2015 Pharma deals in May 2015

    This will all be good practice for Teva as there will be considerable antitrust activity if the Teva-Mylan deal goes ahead.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics